(via NewsDirect)
DuMoulin-White shared the significant findings from the study, revealing that it has provided the primary study treatment to 63 patients. The interim clinical data from Study II shows promising results, with a Complete Response (CR) rate of 54% at 6 months, 38% at 12 months, and 37% at 15 months. These CR rates surpass the guidelines set by the
Additionally, at the 90 Day Assessment Visit, 56% of Evaluable Patients achieved a CR, and 63% achieved a Total Response (CR + IR). At 450 days, 37% achieved a CR, and 41% achieved a TR. The interim clinical data for patients who received the optimized Study II Treatment is even more encouraging. At the 90 Day Assessment Visit, 62% of Evaluable Patients achieved a CR, and 68% achieved a Total Response (CR + IR). At 450 days, 39% achieved a CR, and 44% achieved a TR.
These positive results demonstrate the potential of
Contact Details
Proactive Canada
Proactive
+1 604-688-8158
action@proactiveinvestors.com
Copyright (c) 2024 TheNewswire - All rights reserved.
Copyright (c) 2024 TheNewswire - All rights reserved., source